Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 11:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Thanks for joining us, everybody.

Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, announced today that it has received a $45 million milestone payment from Regeneron Pharmaceuticals, Inc., under the terms of its active collaboration to discover, develop and commercialize engineered Treg therapies for autoimmune diseases. “This payment marks a significant.

Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration

NEW YORK--(BUSINESS WIRE)-- #biotech--Koneksa Announces Regeneron Joins Data Syndication Program for Parkinson's Digital Biomarkers Study.

Koneksa Announces Regeneron Joins Data Syndication Program for Parkinson's Digital Biomarkers Study

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

Regeneron Pharmaceuticals stock reached new all-time highs this month, driven by the Eylea franchise returning to growth in the second quarter, and despite minor regulatory setbacks for the oncology pipeline. Dupixent and Libtayo delivered strong growth in the second quarter. European Commission approvals of Dupixent for COPD and odronextamab for two hematologic malignancies offer some consolation after FDA delays and rejections for the same applications.

Regeneron Stock: Valuation Now Demands More Growth

Harmony Biosciences Holdings

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?

HRMY or REGN: Which Is the Better Value Stock Right Now?

Approval of Ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, including in the post-CAR-T setting

Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)

Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

The U.S. Food and Drug Administration declined to approve Regeneron's therapy for a common form of blood cancer, the company said on Tuesday.

US FDA declines to approve Regeneron's blood cancer therapy

TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for linvoseltamab in relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. This anticipated outcome was previously disclosed during Regeneron's second quarter 2024 earnings call.

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Vertex Pharmaceuticals

Biotech stocks to keep on your radar this month.

2 Biotech Stocks To Watch In August 2024

Anheuser-Busch InBev

Cintas Corp

McDonald's

Rollins

Ross Stores

Walmart

As the dark clouds of a potential recession loom on the horizon, investors are scrambling to find safe havens for their hard-earned money. While it's true that most stocks tend to suffer during economic downturns, there are always a few outliers that manage to defy the odds and emerge stronger than ever.

7 Stocks That Usually Benefit From a Recession

Moderna

Novo Nordisk

Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle.

3 Biotech Stocks Poised for a Comeback After Last Week's Market Meltdown

Bristol-Myers

BioNTech SE

Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.

3 Biotech Stocks With Promising Drug Pipelines: August 2024

McKesson

Universal Health Services

So far in 2024, healthcare stocks have run into periodic earnings challenges compared to historical first quarters. For example, quarterly earnings for healthcare stocks across the board were down 25% compared to first-quarter 2023 earnings.

3 Healthcare Stocks Positioned for Possible Market Outperformance

Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving growth. The next-generation drugs in oncology and obesity are the next potential wave of growth, with even more exciting treatments following them.

Regeneron: Expanded Product Base Taking Root, More Is Certainly On The Way

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

Regeneron shares have recently crossed over the $1,000 price point. The company has achieved significant growth and there could more to come.

Is Regeneron Pharmaceuticals Due for a Stock Split?

Regeneron's Q2 2024 revenue grew 12% year-over-year, reaching $3.55 billion. Dupixent's global net sales increased by 27% to $3.56 billion, driving overall revenue growth. Eylea HD mitigated market share losses by earning $304 million and stabilizing the Eylea franchise.

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

AvalonBay Communities

Public Service Enterprise Group

Over the past month we have observed some very interesting activity across the market's more defensive sectors, considerable outperformance. Below we can see just how significantly the Utilities ( XLU ), Healthcare ( XLV ), Energy ( XLE ) and Real Estate ( XLRE ) sector ETF have outperformed the S&P 500 (in orange).

Defensive Sectors Breakout: 3 Stocks to Buy Now for Protection

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - Executive Vice President, Commercial Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Evan Seigerman - BMO Capital Markets Brian Abrahams - RBC Capital Markets Cory Kasimov - Evercore ISI Christopher Raymond - Piper Sandler Katherine Wang - Jefferies Chris Schott - JPMorgan Tim Anderson - Wolfe Research David Risinger - Leerink Partners Salveen Richter - Goldman Sachs Carter Gould - Barclays Mohit Bansal - Wells Fargo Operator Welcome to the Regeneron Pharmaceuticals Second Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call.

Regeneron Pharmaceuticals, Inc. (REGN) Q2 2024 Earnings Call Transcript

The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Regeneron (REGN) Q2 Earnings: A Look at Key Metrics

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs.

News for Regeneron Pharmaceuticals Stock (REGN)